John Neis

John has extensive experience as a director of portfolio companies, including his current directorships at Cellectar BioSciences (NASDAQ:CLRB) and Delphinus Medical Technologies. He has assisted companies from inception to exit through IPO or acquisition. Past successes include Third Wave Technologies (acquired by Hologic following IPO), TomoTherapy (merged with Accuray following IPO), NimbleGen Systems (acquired by Roche), and Inviragen (acquired by Takeda).  He has been actively engaged in advancing the entrepreneurial ecosystem throughout his career and currently serves on the Board of Directors of the National Venture Capital Association, the Wisconsin Technology Council, and the Board of Trustees for the Morgridge Institute for Research.